Related Experiment Videos
Prostacyclin prevents hyperacute xenogenous rejection of the kidney
Abstract:
The rabbit kidney, perfused under a constant pressure from the canine femoral artery is rejected (i.e. blood flow arrests) within several minutes. It cannot be prevented by intraarterial infusion of strong vasodilatators, such as verapamil and prostaglandin E2. Prostacyclin PGI2 infusion is capable of maintaining a sufficient blood flow and urine production in the rabbit kidney as long as the infusion continues. Once the infusion is interrupted, signs of hyperacute rejection immediately appear. PGI2 or its analogue with a prolonged halflife seem promisive in the treatment of the transplanted kidney rejection.
Insights
Rabbit kidneys rapidly reject canine blood flow, a process unaffected by common vasodilators. Prostacyclin (PGI2) temporarily prevents rejection, suggesting its potential in treating transplanted kidney rejection.
Area of Science:
- Transplantation immunology
- Vascular biology
Background:
- Hyperacute rejection is a major barrier in organ transplantation.
- Rabbit kidneys perfused with canine blood undergo rapid rejection.
Purpose of the Study:
- To investigate the efficacy of vasodilators and prostacyclin in preventing hyperacute rejection in a rabbit kidney model.
- To explore potential therapeutic strategies for transplanted kidney rejection.
Main Methods:
- Rabbit kidneys were perfused under constant pressure from a canine femoral artery.
- Intraarterial infusions of vasodilators (verapamil, prostaglandin E2) and prostacyclin (PGI2) were administered.
- Blood flow and urine production were monitored.
Main Results:
- Kidneys were rejected within minutes without intervention.
- Verapamil and prostaglandin E2 failed to prevent rejection.
- Prostacyclin (PGI2) infusion maintained blood flow and urine production during infusion.
- Rejection signs reappeared immediately upon PGI2 interruption.
Conclusions:
- Hyperacute rejection in this model is resistant to standard vasodilators.
- Prostacyclin (PGI2) demonstrates significant potential in preventing early kidney transplant rejection.
- PGI2 or its analogues may offer a promising therapeutic approach for managing transplanted kidney rejection.